TABLE 1.
Participant clinical and HIV sequence sampling details
| Participant | Clinically estimated infection date | Diagnosis date | First plasma viral load, copies/ml (log10)a | No. of plasma time points with HIV sequence datab | No. of plasma HIV sequences (distinct: no.; %)c | ART initiation date | Total proviral burden on ART (% genomically intact)d | Proviral sequencing date(s) | No. of proviral sequences (distinct: no.; %)c |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Apr 2006 | Feb 2007 | 1,615 (3.21) | 8 | 104 (52; 50) | 1 Aug 2010 | 215 (51) | 13 Sept 2012 | 48 (40; 83) |
| 2 | Dec 2005 | Jan 2006 | 977 (2.99) | 9 | 67 (60; 90) | 1 May 2014 | 580 (10) | 8 Sept 2015 | 66 (36; 55) |
| 3 | Mar 2008 | Jun 2008 | 97 (1.99) | 7 | 130 (71; 55) | 1 Jan 2012 | 44 (31) | 14 Jul 2016 | 24 (12; 50) |
| 4 | Mar 2005 | Nov 2005 | 383 (2.58) | 12 | 245 (173; 71) | 1 Feb 2013 | 778 (94) | 18 Nov 2013 | 1 full genome |
| 20 Oct 2014 | 128 (119; 92) |
a
First detectable sampled plasma viral load, expressed as HIV RNA copies/ml plasma.
b
Total number of plasma time points from which HIV RNA nef sequences were successfully amplified.
c
“Distinct” refers to sequences that were observed only once in that compartment. Reported numbers exclude defective, hypermutated, and putative within-host recombinant HIV sequences.
d
As measured by the intact proviral DNA assay and expressed as HIV copies/106 CD4+ T cells.